
Neurogene Publishes Study on NGN-401 Gene Therapy for Rett Syndrome
Neurogene Publishes Study on NGN-401 Gene Therapy for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company dedicated to developing transformative genetic medicines for patients suffering from rare neurological…













